報價延遲最少15分鐘:2026/04/21 19:27 EDT
盤後時段
|
||||
|
2.52 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.52
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.49/--
|
|
企業價值
76.52M
|
| 資產負債 |
|
每股賬面淨值
4.60
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
0.06
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy. |
